News

Heptares bags Takeda milestones
Enlarge image

BusinessUKSwitzerlandGermany

Heptares bags Takeda milestones

30.04.2013 - British GPCR specialist Heptares Therapeutics has achieved all milestones in its collaboration with Japanese pharma major Takeda Pharmaceutical.

Under the two-year £65m drug discovery alliance signed in April 2011, Heptares will cash in up to £1m research-stage milestones. The British company's success in stabilising a GPCR target that up to now was undruggable because it regularly degraded when removed from the cell membrane. Heptares succeeded to generate a stable but clinical relevant form of Takeda’s target molecule enabling rational design of different leads. 

Takeda General Manager Tetsuyuki Maruyama announced that the leads will be taken forward now into pre-clinical development. Under the terms of the agreement, Takeda receives worldwide commercial rights to new drugs emerging from the collaboration. Upon signing, Heptares received an upfront payment of £1.7 million and an investment in an equity stake of approximately £2.8 million purchased by Takeda Ventures Inc., a wholly-owned subsidiary of Takeda. Heptares is eligible to receive $96 million in additional later-stage milestones plus royalties on product sales.

Heptares announced that the milestone fees will be used to finance the initiation of clinical studies with its proprietary drug candidate, a first-in-class selective M1 agonist later this year. The company’s pharmaceutical partners include Shire, AstraZeneca, MedImmune, Morphosys, Takeda and Cubist. 

© eurobiotechnews.eu/tg

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

BioeconomyFranceEU

01.04.2014 The European Commission has approved a French state package aid worth €43m for green chemistry project IEED.

MonitoringEU

27.03.2014 In Europe, bacterial resistance to prevalent antimicrobials is common, while multi-resistance remains low, EFSA and ECDC now report.

FinancingFrance

25.03.2014 Immunotherapy developer Transgene SA has successfully raised a total of €65.5m via a two-step capital increase – including a rights issue and a private placement.

Events

All Events

Partner-Events

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS (CH)0.23 CHF53.3%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • CO.DON (D)3.40 EUR9.7%

FLOP

  • WILEX (D)0.88 EUR-15.4%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • FLAMEL TECHNOLOGIES (F)11.01 USD-13.5%

TOP

  • CO.DON (D)3.40 EUR91.0%
  • WILEX (D)0.88 EUR51.7%
  • BIOTECH PHARMACON (N)17.50 NOK50.9%

FLOP

  • CYTOS (CH)0.23 CHF-92.0%
  • BIONOR PHARMA (N)2.11 NOK-47.9%
  • GW PHARMACEUTICALS (UK)219.50 GBP-46.5%

TOP

  • SILENCE THERAPEUTICS (UK)255.00 GBP5900.0%
  • IXICO (UK)69.50 GBP776.4%
  • PLETHORA (UK)11.00 GBP609.7%

FLOP

  • CYTOS (CH)0.23 CHF-94.7%
  • EVOCUTIS (UK)0.22 GBP-92.9%
  • AGENNIX (D)0.04 EUR-78.9%

No liability assumed, Date: 15.04.2014